MaxCyte
ExPERT STx™ Scalable static or flow electroporation | MaxCyte
The industry’s leading scalable electroporation technology for high-yield, transient expression of complex proteins, vaccines and biologics.
- Rapidly transfect from 75 thousand to 20 billion cells
- High efficiency enables flexible media strategies that can deliver significant cost savings
- Improved yields for decreased development timelines
- Proprietary Flow Electroporation™ Technology
- Faster production of stable clones
- ISO-certified and CE-marked
Supporting Documents
Scientific Brief
MaxCyte® Enabled Innovative SARS-CoV-2 Vaccine Development
You don't want to miss this!
To permanently access these supporting documents, fill out the short form below.
ALREADY ACCESSED THESE DOCUMENTS? SIGN IN
More Scientific Products from MaxCyte
-
APR 30, 2024Immuno-Oncology Virtual Event Series 2024 -
MAY 07, 20243rd International Biosecurity Virtual Symposium
-
MAY 23, 2024For the Love of Digital PCR 2024
- See More
-
MAY 07, 2024Is It Anti-RNP or Anti-Sm/RNP?
-
MAY 08, 2024Expand your Multiomic Capabilities with RNAscope™
- See More
